Molecular Partners Ag (MOLN) FCF Margin (2020 - 2024)
Molecular Partners Ag's (MOLN) quarterly FCF Margin came in at 261.44% in Q4 2024, down 3832.0% year-over-year from 7.01% in Q1 2024, and up 99.99% quarter-over-quarter from 1912628.49% in Q3 2024.
Powered by 
Analysis
Molecular Partners Ag (MOLN) FCF Margin (2020 - 2024) Analysis & Trends
Molecular Partners Ag (MOLN) has reported FCF Margin for 5 consecutive years, with 261.44% the latest figure, recorded in Q4 2024.
- On a quarterly basis, FCF Margin fell 3832.0% year-over-year to 261.44% in Q4 2024; TTM through Jun 2026 was 1013.98%, a 12721.0% decrease from a year earlier, with the FY2024 full-year figure at 1170.86%, down 34065.0% from the prior year.
- FCF Margin was 261.44% for Q4 2024 at Molecular Partners Ag, up from 1912628.49% in the prior quarter.
- Over five years, FCF Margin peaked at 1513228.93% in Q3 2021 and troughed at 6373484.26% in Q3 2022.
- A 5-year average of 461442.09% and a median of 929.92% in 2021 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin slumped 788671319 bps in 2022 and jumped 585793920 bps in 2023, its largest moves.
- Over 5 years, FCF Margin stood at 617.87% in 2020, then tumbled by 51 bps to 929.92% in 2021, then jumped by 107 bps to 62.83% in 2022, then sank by 455 bps to 223.12% in 2023, then dropped by 17 bps to 261.44% in 2024.
- The last three FCF Margin figures came in at 261.44% (Q4 2024), 1912628.49% (Q3 2024), and 2099.55% (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -18,629.40% |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -261.44% |
| Sep 30, 2024 | -1,912,628.49% |
| Jun 30, 2024 | -2,099.55% |
| Mar 31, 2024 | 3,833.13% |
| Dec 31, 2023 | -223.12% |
| Sep 30, 2023 | -515,545.06% |
| Jun 30, 2023 | -3,171.33% |
| Mar 31, 2023 | -540,295.08% |
| Dec 31, 2022 | 62.83% |
| Sep 30, 2022 | -6,373,484.26% |
| Jun 30, 2022 | 1,289.30% |
| Mar 31, 2022 | -106.75% |
| Dec 31, 2021 | -929.92% |
| Sep 30, 2021 | 1,513,228.93% |
| Jun 30, 2021 | -1,194.09% |
| Mar 31, 2021 | -12,372.77% |
| Dec 31, 2020 | -617.87% |